CorMedix Inc. (NASDAQ:CRMD) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET
Company Participants
Daniel Ferry - LifeSci Advisors
Joseph Todisco - Chief Executive Officer
Matt David - Executive Vice President and Chief Financial Officer
Phoebe Mounts - Executive Vice President and General Counsel
Elizabeth Hulbert - EVP, Clinical and Medical Affairs
Erin Mistry - Executive Vice President and Chief Commercial Officer
Conference Call Participants
Jason Butler - JMP Securities
Joon Lee - Truist Securities.
Rohit Bhasin - Needham & Company
Operator
Greetings, and welcome to CorMedix, Inc. Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Thank you, Mr. Ferry, you may begin.
Daniel Ferry
Good morning, and welcome to the CorMedix Second Quarter 2023 Earnings Conference Call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix. And he is joined by Dr. Matt David, Executive Vice President and CFO; Dr. Phoebe Mounts, EVP and General Counsel; Liz Hulbert, EVP of Clinical and Medical Affairs; and Erin Mistry, EVP and Chief Commercial Officer.
Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include, but are not limited to, any of the following: any statements other than statements of historical fact regarding management's expectations, beliefs, goals and plans about the Company's prospects, including its clinical development program, manufacturing activities and NDA approval for DefenCath in the U.S. or other product candidates; future financial position; future revenues and projected costs and reimbursement and potential market acceptance of DefenCath or other product candidates.
More specifically, forward-looking statements include any statements about our clinical development plans and the timing, cost, progress, results, estimates and interpretations thereof; projections as to the Company's future capital raising and spending and cash position; including projections regarding the sufficiency of the Company's current cash resources to potentially bring the Company through to breakeven profitability, expectations as to the timing and nature of anticipated regulatory actions, reimbursement decisions, possible product licensing, business development or other transactions; any commercial plans and expectations; intellectual property protections for our product candidates, market projections for our product candidates; and expectations as to manufacturing and product component costs.